A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Part 1: Objective Response Rate (ORR)

• Objective response rate is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST 1.1, by dose level.

Time frame: Up to 30 days following last adminstration

Part 2: Occurence of Adverse Events by Severity

• An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE in Part 2 will be reported.

Time frame: Up to End of Treatment (30 days after the last dose)

Part 1 and 2: Duration of Response (DOR)

• Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause.

Time frame: Up to 5 years after first administration

Part 1 and 2: Progression-Free Survival (PFS)

• PFS is defined as the time from treatment initiation to the first documented disease progression per RECIST 1.1 or death due to any cause, whichever occurs first.

Time frame: Up to 5 years after first administration